Hospital
River Oaks Hospital LLC
River Oaks Hospital LLC was paid $16.59M by Medicaid between Jan 2018 and Dec 2024, across 211 billing codes. Its largest line is 99283, emergency room visit (moderate) — 20% of everything it billed.
33Billing provider infoRIVER OAKS HOSPITAL LLC
FLOWOOD, MS 39232
FLOWOOD, MS 39232
33aNPI1396792032assigned 05/28/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$16.59M
24GClaims521,171
24DCodes billed211
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Mississippi
Rank by total paid#30 of 77
Median peer was paid$8.23M
This provider vs. median2.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LALOR, PAULA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 74,379 | $2.94M | |
| 2019 | 68,252 | $2.97M | |
| 2020 | 61,931 | $1.99M | |
| 2021 | 74,604 | $2.33M | |
| 2022 | 98,424 | $2.62M | |
| 2023 | 88,385 | $2.18M | |
| 2024incomplete | 55,196 | $1.56M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 20% | 27,816 | 20,726 | $3.31M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 12,674 | 9,464 | $2.03M |
| G0378 | Hospital observation service, per hour | 6.2% | 4,487 | 3,047 | $1.03M |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 4.7% | 1,151 | 631 | $788K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.6% | 8,029 | 6,298 | $602K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.5% | 7,699 | 5,642 | $585K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.5% | 2,997 | 2,252 | $576K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 3.0% | 11,064 | 2,893 | $496K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.8% | 2,970 | 2,238 | $472K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 2.7% | 11,202 | 2,561 | $444K |
| D7140 | Extraction, erupted tooth or exposed root | 2.4% | 1,029 | 278 | $393K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.0% | 8,303 | 6,356 | $336K |
199 more codes
| D2930 | Prefabricated stainless steel crown - primary tooth | 2.0% | 6,931 | $335K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 2.0% | 3,555 | $325K |
| 87428 | 1.6% | 6,082 | $267K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.6% | 8,128 | $267K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 1.6% | 129 | $266K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.6% | 5,156 | $262K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | 1.5% | 1,725 | $248K |
| 71046 | Radiologic examination, chest; 2 views | 1.2% | 5,987 | $201K |
| 71045 | Radiologic examination, chest; single view | 1.2% | 5,705 | $194K |
| 86900 | 1.0% | 4,012 | $171K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 9,727 | $155K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 2,864 | $132K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,614 | $131K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,507 | $129K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,806 | $106K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 3,738 | $106K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 24,086 | $105K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 7,399 | $102K |
| 80053 | Comprehensive metabolic panel | <1% | 15,906 | $94K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 878 | $93K |
| 87641 | <1% | 5,150 | $91K | |
| D2934 | <1% | 1,281 | $90K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 4,474 | $88K |
| 74018 | <1% | 2,082 | $77K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,922 | $74K |
| 87430 | <1% | 5,924 | $65K | |
| 86850 | <1% | 3,324 | $60K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 31,526 | $58K |
| 86901 | <1% | 4,018 | $52K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 518 | $43K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 692 | $43K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 361 | $41K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,408 | $41K |
| 84703 | <1% | 8,005 | $40K | |
| 76801 | <1% | 620 | $39K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 6,820 | $38K |
| 97161 | <1% | 1,103 | $37K | |
| 73560 | <1% | 1,117 | $35K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,353 | $35K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 173 | $33K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,544 | $33K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,843 | $31K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,206 | $27K |
| 81001 | <1% | 13,869 | $26K | |
| 87070 | <1% | 4,043 | $26K | |
| 73610 | <1% | 682 | $26K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,757 | $26K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 267 | $26K |
| 84484 | <1% | 3,843 | $25K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 478 | $24K |
| 80061 | Lipid panel | <1% | 2,730 | $24K |
| 88720 | <1% | 6,058 | $22K | |
| 94762 | <1% | 486 | $22K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,000 | $20K |
| 92526 | <1% | 424 | $20K | |
| 73630 | <1% | 489 | $19K | |
| 84702 | <1% | 2,019 | $19K | |
| 83690 | <1% | 3,623 | $16K | |
| 83880 | <1% | 1,037 | $16K | |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | <1% | 629 | $14K |
| 73221 | <1% | 107 | $12K | |
| 72100 | <1% | 244 | $10K | |
| 81003 | <1% | 6,346 | $10K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 214 | $9K |
| 72141 | <1% | 114 | $9K | |
| 85730 | <1% | 3,486 | $9K | |
| 87186 | <1% | 1,409 | $8K | |
| 81025 | <1% | 1,664 | $8K | |
| 85610 | <1% | 4,325 | $8K | |
| 73130 | <1% | 182 | $7K | |
| D3220 | Therapeutic pulpotomy (excluding final restoration) - removal of pulp coronal to the dentinocemental junction | <1% | 389 | $7K |
| 87077 | <1% | 1,328 | $7K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 255 | $7K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 254 | $7K |
| 82962 | <1% | 3,831 | $7K | |
| 87807 | <1% | 669 | $7K | |
| D2330 | <1% | 311 | $6K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,550 | $6K |
| 97116 | <1% | 991 | $6K | |
| 92523 | <1% | 40 | $6K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 155 | $6K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 129 | $5K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 10,542 | $5K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,085 | $5K |
| 73030 | <1% | 161 | $5K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 150 | $5K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,525 | $5K |
| 83605 | <1% | 894 | $5K | |
| 87040 | <1% | 800 | $5K | |
| 72131 | <1% | 125 | $4K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 11,259 | $4K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 2,432 | $4K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 7,677 | $4K |
| 72040 | <1% | 124 | $4K | |
| 82247 | <1% | 1,209 | $4K | |
| 85014 | <1% | 2,580 | $4K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,595 | $3K |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 3,070 | $3K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 261 | $3K |
| J2704 | Injection, propofol, 10 mg | <1% | 7,913 | $3K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 9,156 | $3K |
| 85652 | <1% | 947 | $3K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 10,041 | $3K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 5,481 | $3K |
| 86140 | <1% | 868 | $3K | |
| 74019 | <1% | 50 | $3K | |
| 83735 | <1% | 985 | $3K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 28 | $3K |
| 82540 | <1% | 736 | $2K | |
| 73110 | <1% | 77 | $2K | |
| 84132 | <1% | 848 | $2K | |
| 82607 | <1% | 369 | $2K | |
| 93971 | <1% | 72 | $2K | |
| 84439 | <1% | 318 | $2K | |
| 93970 | <1% | 27 | $2K | |
| 82728 | <1% | 249 | $1K | |
| 87205 | <1% | 424 | $1K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,083 | $1K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 16 | $1K |
| 97165 | <1% | 37 | $1K | |
| 76830 | Ultrasound, transvaginal | <1% | 24 | $1K |
| 85027 | <1% | 468 | $919.74 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 234 | $900.35 |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 22 | $872.61 |
| 84520 | <1% | 310 | $830.40 | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 24 | $768.36 |
| 85018 | <1% | 704 | $765.22 | |
| 93041 | <1% | 86 | $738.19 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 364 | $706.91 |
| 84550 | <1% | 221 | $658.54 | |
| 82731 | <1% | 16 | $595.12 | |
| 97162 | <1% | 13 | $589.46 | |
| 72110 | <1% | 21 | $551.14 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,653 | $515.88 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 35 | $448.50 |
| 84450 | <1% | 149 | $445.72 | |
| 85379 | <1% | 68 | $383.09 | |
| 93979 | <1% | 20 | $344.36 | |
| 82550 | <1% | 101 | $343.30 | |
| 82565 | <1% | 261 | $328.76 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 18 | $323.40 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,223 | $281.81 |
| J7121 | 5% dextrose in lactated ringers infusion, up to 1000 cc | <1% | 2,022 | $270.02 |
| 82947 | <1% | 230 | $261.65 | |
| 83540 | <1% | 105 | $241.62 | |
| 80076 | <1% | 39 | $223.77 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,111 | $177.99 |
| 86780 | <1% | 18 | $145.77 | |
| 82746 | <1% | 56 | $127.02 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 369 | $125.85 |
| 82570 | <1% | 38 | $103.95 | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 48 | $84.72 |
| 83615 | <1% | 14 | $76.46 | |
| 87147 | <1% | 14 | $67.15 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,834 | $53.22 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 69 | $39.81 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 954 | $17.16 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 1,361 | $7.44 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 496 | $3.10 |
| Q0177 | Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 196 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 104 | $0.00 |
| C1758 | Catheter, ureteral | 0% | 841 | $0.00 |
| 94664 | 0% | 436 | $0.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 233 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 894 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 148 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 83 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 265 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 952 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 131 | $0.00 |
| 99152 | 0% | 293 | $0.00 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 199 | $0.00 |
| C1776 | Joint device (implantable) | 0% | 109 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 49 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 48 | $0.00 |
| C1762 | Connective tissue, human (includes fascia lata) | 0% | 80 | $0.00 |
| G1002 | Clinical decision support mechanism medcurrent, as defined by the medicare appropriate use criteria program | 0% | 29 | $0.00 |
| 90714 | 0% | 21 | $0.00 | |
| J0595 | Injection, butorphanol tartrate, 1 mg | 0% | 23 | $0.00 |
| 96376 | 0% | 1,414 | $0.00 | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 0% | 463 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 446 | $0.00 |
| C1769 | Guide wire | 0% | 292 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 3,522 | $0.00 |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 380 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 43 | $0.00 |
| 90378 | 0% | 266 | $0.00 | |
| J3490 | Unclassified drugs | 0% | 170 | $0.00 |
| 97535 | Self-care/home management training, each 15 minutes | 0% | 160 | $0.00 |
| 0240U | 0% | 128 | $0.00 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 109 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 67 | $0.00 |
| 96111 | 0% | 144 | $0.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 33 | $0.00 |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 0% | 36 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 20 | $0.00 |
| 80349 | 0% | 18 | $0.00 | |
| 94760 | 0% | 27 | $0.00 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 25 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLALOR, PAULA (DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| Roswell Hospital Corporation | Roswell, NM | $41.27M |
| Wesley Health System LLC | Hattiesburg, MS | $37.82M |
| Metro Knoxville Hma LLC | Powell, TN | $28.70M |
| Bullhead City Hospital Corporation | Bullhead City, AZ | $28.54M |
| Iom Health System LP | Fort Wayne, IN | $27.50M |
| ST. Joseph Health System, LLC | Fort Wayne, IN | $25.43M |
| Laredo Texas Hospital Company LP | Laredo, TX | $19.46M |
| Oak Hill Hospital Corporation | Oak Hill, WV | $18.77M |
| Cocke County Hma, LLC | Newport, TN | $18.34M |
| Cleveland Tennessee Hospital Company LLC | Cleveland, TN | $16.31M |
| Jefferson County Hma LLC | Jefferson City, TN | $14.31M |
| Northwest Arkansas Hospitals, LLC | Springdale, AR | $11.46M |
| Petersburg Hospital Company LLC | Petersburg, VA | $11.20M |
| Campbell County Hma, LLC | Lafollette, TN | $10.07M |
| Warsaw Health System LLC | Warsaw, IN | $9.95M |
| Longview Medical Center LP | Longview, TX | $9.29M |
| Moberly Hospital Company LLC | Moberly, MO | $8.61M |
| Crestview Hospital Company, LLC | Crestview, FL | $8.15M |
| Kirksville Missouri Hospital Company, LLC | Kirksville, MO | $7.98M |
| Victoria of Texas LP | Victoria, TX | $7.74M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.